4-(6-methyl-2-phenylpyrimidin-4-ylamino)benzoic acid | 312626-15-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(6-methyl-2-phenylpyrimidin-4-ylamino)benzoic acid
• 英文别名: Agn-PC-0jxbal；4-[(6-methyl-2-phenylpyrimidin-4-yl)amino]benzoic acid
• CAS: 312626-15-6
• 化学式: C₁₈H₁₅N₃O₂
• mdl: MFCD01446848
• 分子量: 305.336
• InChiKey: PDUDPXZEQCFLNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  75.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE<br/>[FR] COMPOSÉS ACTIVANT NURR1:RXR POUR LE TRAITEMENT SIMULTANÉ DES SYMPTÔMES ET DE LA PATHOLOGIE DE LA MALADIE DE PARKINSON
  申请人：VASSILATIS DEMETRIOS K

  公开号：WO2017068070A1

  公开（公告）日：2017-04-27

  The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeutics to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the symptoms of such diseases and therefore represent a new treatment modality for ameliorating chronic and acute conditions. The compounds of the invention are capable of selectively potentiating the activity of the Nurr1:RXRα heterodimer, and are able to treat diseases or conditions associated with aberrant Nurr1:RXRα function. The invention further provides methods for treating neurodegenerative disorders by administration of Nurr1:RXRα activating agents.

  这项发明提供了一系列取代芳基嘧啶化合物，并利用这些化合物作为治疗剂来治疗或预防神经退行性疾病，包括帕金森病。该发明的化合物还能够治疗这些疾病的症状，因此代表了一种新的治疗方式，用于改善慢性和急性病症。该发明的化合物能够选择性地增强Nurr1:RXRα异源二聚体的活性，并能够治疗与异常Nurr1:RXRα功能相关的疾病或病症。该发明还提供了通过给予Nurr1:RXRα激活剂来治疗神经退行性疾病的方法。
• Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease
  申请人：Vassilatis Demetrios K.

  公开号：US10946019B2

  公开（公告）日：2021-03-16

  The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeutics to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the symptoms of such diseases and therefore represent a new treatment modality for ameliorating chronic and acute conditions. The compounds of the invention are capable of selectively potentiating the activity of the Nurr1:RXRα heterodimer, and are able to treat diseases or conditions associated with aberrant Nurr1:RXRα function. The invention further provides methods for treating neurodegenerative disorders by administration of Nurr1:RXRα activating agents.

  本发明提供了一系列取代芳基嘧啶化合物，并将这些化合物用作治疗或预防神经退行性疾病（包括帕金森病）的药物。本发明的化合物还能治疗此类疾病的症状，因此是一种改善慢性和急性疾病的新治疗方式。本发明的化合物能够选择性地增强Nurr1:RXRα异二聚体的活性，能够治疗与Nurr1:RXRα功能异常相关的疾病或病症。本发明进一步提供了通过施用 Nurr1:RXRα 激活剂治疗神经退行性疾病的方法。
• NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE
  申请人：Vassilatis, Demetrios K.

  公开号：EP3365329B1

  公开（公告）日：2022-03-30
• US8455489B2
  申请人：——

  公开号：US8455489B2

  公开（公告）日：2013-06-04